Latest Information Update: 24 Jun 2002
At a glance
- Originator ALTANA Pharma
- Mechanism of Action Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 01 May 2002 Discontinued - Phase-I for Gastro-oesophageal reflux in Germany (unspecified route)
- 11 Nov 1999 Phase-I clinical trials for Gastro-oesophageal reflux in Germany (Unknown route)